These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 9051718)
21. Myocardial ischemia-mediated excitatory reflexes: a new function for thromboxane A2? Fu LW; Phan A; Longhurst JC Am J Physiol Heart Circ Physiol; 2008 Dec; 295(6):H2530-40. PubMed ID: 18952714 [TBL] [Abstract][Full Text] [Related]
22. Thromboxane A2 antagonist and diltiazem-induced enhancement of contractile function: the effect of timing of treatment. Grover GJ; Fulmor IE J Pharmacol Exp Ther; 1988 Nov; 247(2):445-52. PubMed ID: 3183946 [TBL] [Abstract][Full Text] [Related]
23. Thromboxane A2 receptor mediation of calcium and calcium transients in rat cardiomyocytes. Dogan S; Turnbaugh D; Zhang M; Cofie DQ; Fugate RD; Kem DC Life Sci; 1997; 60(12):943-52. PubMed ID: 9061051 [TBL] [Abstract][Full Text] [Related]
24. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries. Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517 [TBL] [Abstract][Full Text] [Related]
25. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005 [TBL] [Abstract][Full Text] [Related]
26. Antagonism of thromboxane actions in the isolated perfused rat heart. Stahl GL; Darius H; Lefer AM Life Sci; 1986 Jun; 38(22):2037-41. PubMed ID: 2940431 [TBL] [Abstract][Full Text] [Related]
27. Beneficial effects of combined thromboxane and leukotriene receptor antagonism in hemorrhagic shock. Patel JP; Beck LD; Briglia FA; Hock CE Crit Care Med; 1995 Feb; 23(2):231-7. PubMed ID: 7867347 [TBL] [Abstract][Full Text] [Related]
28. Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injury. Squadrito F; Ioculano M; Altavilla D; Zingarelli B; Canale P; Campo GM; Saitta A; Oriti S; Faggiotto A; Caputi AP Agents Actions; 1993 Jul; 39(3-4):143-9. PubMed ID: 8304242 [TBL] [Abstract][Full Text] [Related]
29. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro. O'Keefe EH; Liu EC; Greenberg R; Ogletree ML Prostaglandins; 1985 May; 29(5):785-97. PubMed ID: 3925501 [TBL] [Abstract][Full Text] [Related]
30. Thromboxane A2 receptor antagonism prevents hormonal and cardiovascular responses to mineral acid infusion. Cudd TA; Wood CE Am J Physiol; 1994 Nov; 267(5 Pt 2):R1235-40. PubMed ID: 7977850 [TBL] [Abstract][Full Text] [Related]
32. Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations. Yao SK; Rosolowsky M; Anderson HV; Golino P; NcNatt JM; De Clerck F; Buja LM; Willerson JT J Am Coll Cardiol; 1990 Sep; 16(3):705-13. PubMed ID: 2143767 [TBL] [Abstract][Full Text] [Related]
33. The combined antiischemic effects of the thromboxane receptor antagonist SQ 30,741 and tissue-type plasminogen activator. Grover GJ; Parham CS; Schumacher WA Am Heart J; 1991 Feb; 121(2 Pt 1):426-33. PubMed ID: 1825008 [TBL] [Abstract][Full Text] [Related]
34. Anti-ischemic actions of a new thromboxane receptor antagonist during acute myocardial ischemia in cats. Brezinski ME; Yanagisawa A; Darius H; Lefer AM Am Heart J; 1985 Dec; 110(6):1161-7. PubMed ID: 3000159 [TBL] [Abstract][Full Text] [Related]
35. Effect of thromboxane receptor blockade on oxygen supply/consumption variables during reperfusion in the anesthetized dog. Grover GJ; Sleph PG; Weiss HR J Pharmacol Exp Ther; 1990 Jun; 253(3):1097-102. PubMed ID: 2141635 [TBL] [Abstract][Full Text] [Related]
36. The effect of halothane anesthesia on myocardial necrosis, hemodynamic performance, and regional myocardial blood flow in dogs following coronary artery occlusion. Davis RF; DeBoer LW; Rude RE; Lowenstein E; Maroko PR Anesthesiology; 1983 Nov; 59(5):402-11. PubMed ID: 6638546 [TBL] [Abstract][Full Text] [Related]
38. Beneficial actions of the thromboxane receptor antagonist, AH-23,848, in acute myocardial ischemia. Brezinski ME; Osborne JA; Yanagisawa A; Lefer AM Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):703-9. PubMed ID: 2966270 [TBL] [Abstract][Full Text] [Related]
39. Protective effect of a novel thromboxane synthetase inhibitor, CV-4151, on myocardial damage due to coronary occlusion and reperfusion in the hearts of anesthetized dogs. Imamoto T; Terashita Z; Tanabe M; Nishikawa K; Hirata M J Cardiovasc Pharmacol; 1986; 8(4):832-9. PubMed ID: 2427826 [TBL] [Abstract][Full Text] [Related]
40. Correction of ischaemic brain acidosis with SQ29,548/1-benzylimidazole. Pettigrew LC; Hazle JD; Gutierrez G; Smith CD; Ogletree ML Neurol Res; 1992 Sep; 14(4):335-9. PubMed ID: 1360630 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]